Evidence map›Paper›PMID 40242581›Full record

ArticleACS pharmacology & translational science2025

Jonas Hildebrandt, Dirk O Bauerschlag, Gert Fricker, Ulrich Girreser, Björn Konukiewitz, Franziska Kellers, Nicolai Maass, Bernd Clement, Inken Flörkemeier

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jonas HildebrandtChristian-Albrechts-University Kiel, Pharmaceutical Institute, Department of Pharmaceutical and Medicinal Chemistry, Kiel 24118, Germany.
Dirk O BauerschlagDepartment of Gynaecology and Obstetrics, University and University Medical Center Schleswig-Holstein Campus Kiel, Kiel 24105, Germany.
Gert FrickerRuprecht-Karls University, Institute of Pharmacy and Molecular Biotechnology, Heidelberg 69120, Germany.ORCID https://orcid.org/0000-0003-3894-961X
Ulrich GirreserChristian-Albrechts-University Kiel, Pharmaceutical Institute, Department of Pharmaceutical and Medicinal Chemistry, Kiel 24118, Germany.
Björn KonukiewitzDepartment of Pathology, University and University Medical Center Schleswig-Holstein Campus Kiel, Kiel 24105, Germany.
Franziska KellersDepartment of Pathology, University and University Medical Center Schleswig-Holstein Campus Kiel, Kiel 24105, Germany.
Nicolai MaassDepartment of Gynaecology and Obstetrics, University and University Medical Center Schleswig-Holstein Campus Kiel, Kiel 24105, Germany.
Bernd ClementChristian-Albrechts-University Kiel, Pharmaceutical Institute, Department of Pharmaceutical and Medicinal Chemistry, Kiel 24118, Germany.ORCID https://orcid.org/0000-0003-1412-6117
Inken FlörkemeierChristian-Albrechts-University Kiel, Pharmaceutical Institute, Department of Pharmaceutical and Medicinal Chemistry, Kiel 24118, Germany.ORCID https://orcid.org/0000-0001-5885-6352

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to high mortality rates, new and more effective drugs are urgently needed in cancer therapy. The novel dual topoisomerase inhibitor P8-D6, a dimethylaminoethyl-substituted pyridophenanthroline, showed

Identifiers

PMID40242581
PMCPMC11997890

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.